aspirin in Alzheimer's disease
Last reviewed 02/2021
- aspirin in Alzheimer's disease (AD)
- study evidence revealed that treatment with low-dose aspirin had no worthwhile benefit in patients with AD and increased the risk of serious bleeds (1)
- the AD2000 study shows that, for patients with AD and no clinically evident cardiovascular disease, transient ischaemic attack, or stroke, 2 years of treatment with low-dose aspirin
- 8% patients on aspirin and 1% patients in the control group had bleeds that led to admission to hospital (relative risk=4·4, 95% CI 1·5–12·8; p=0·007); 2% patients in the aspirin group had fatal cerebral bleeds.